Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
104 consecutively resected lung adenocarcinomas from 396 non-smoker females (less than 100 cigarettes in a lifetime) at a single institution (Tongji University, Shanghai, China) were analyzed for mutations in EGFR, EML4-ALK, KRAS, HER2, BRAF, and PIK3CA.
|
22707299 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
|
22124476 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
CTD_human |
EML4-ALK fusion gene, is found in 3 to 5 % of lung adenocarcinoma and can be targeted by tyrosine-kinase inhibitor (TKI) with impressive therapeutic results.
|
22980554 |
2012 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report.
|
23664446 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
EML4-ALK rearrangement is detected in 2% to 7% of lung adenocarcinomas, these tumors are sensitive to crizotinib.
|
26045865 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusions represent the majority of ALK rearrangements in lung adenocarcinomas and were, until recently, thought to be exclusive to that tumour type.
|
26880345 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 253 patients with advanced lung adenocarcinoma received a pemetrexed-based regimen and were classified on the basis of molecular findings as follows: 102 patients (40.3%) with EGFR mutations, 32 patients (12.6%) with EML4-ALK translocation, three patients (1.2%) with KRAS mutations, 19 patients (7.5%) with ROS1 fusion, and 97 patients (38.3%) with quadruple-negative status.
|
27094798 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
|
30133144 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although the frequency of EML4-ALK rearrangements is lower in lung SqCC than that in lung adenocarcinomas, their presence may provide additional treatment options in lung SqCC.
|
25527865 |
2014 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among the 440 patients with adenocarcinoma of lung screened for this study, 46 (10.4%) harboured the EML4-ALK fusion, 90 (20.4%) harboured an activating EGFR mutation, and all had adenocarcinoma.
|
24361161 |
2014 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of ERBB ligand-induced resistance mechanism to crizotinib by primary culture of lung adenocarcinoma with EML4-ALK fusion gene.
|
25695223 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Anaplastic lymphoma kinase (ALK) fuses echinoderm microtubule-associated protein-like 4 (EML4) to acquire a transforming activity in lung adenocarcinomas.
|
23787064 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
BRAF mutations were analysed by DNA sequencing of a Caucasian subpopulation of selected 450 of 1509 (30%) EGFR, KRAS, PI3KA, Her2 and EML4-ALK wild-type (wt) primary lung adenocarcinomas.
|
23131393 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Concomitant EGFR Mutation and EML4-ALK Rearrangement in Lung Adenocarcinoma Is More Frequent in Multifocal Lesions.
|
31138506 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma.
|
27078848 |
2016 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
|
23625156 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides.
|
23408463 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma.
|
26142544 |
2015 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Dual drive coexistence of EML4-ALK and TPM3-ROS1 fusion in advanced lung adenocarcinoma.
|
29251824 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Evidence that the lung Adenocarcinoma EML4-ALK fusion gene is not caused by exposure to secondhand tobacco smoke during childhood.
|
24755712 |
2014 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression.
|
20624322 |
2010 |
Adenocarcinoma of lung (disorder)
|
0.400 |
Biomarker
|
disease |
BEFREE |
Heat shock protein 90 (HSP90) is an important chaperone in lung adenocarcinoma, with relevant protein drivers such as EGFR (epidermal growth factor receptor) and EML4-ALK (echinoderm microtubule-associated protein-like protein4 fused to anaplastic lymphoma kinase) depending on it for their correct function, therefore HSP90 inhibitors show promise as potential treatments for lung adenocarcinoma.
|
31370342 |
2019 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, the association between MAGE-A expression and the epithelial growth factor receptor (EGFR) amplification and ALK-EML4 rearrangements of patients with LAC were also analysed.
|
27864450 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this series, 230 resected lung adenocarcinomas from smoker (>100 cigarettes in lifetime) at single center (Shanghai Cancer Center, Shanghai, China) were tested for mutation in EGFR, KRAS, BRAF, HER2, EML4-ALK and PIK3CA.
|
23098378 |
2013 |
Adenocarcinoma of lung (disorder)
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we found that the lung adenocarcinoma cell line A925L expresses an EML4-ALK gene fusion (variant 5a, E2:A20) and is sensitive to the ALK inhibitors crizotinib and alectinib.
|
25581823 |
2015 |